Screener
Mineralys Therapeutics, Inc. MLYS Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Mineralys Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The source filing: Mineralys Therapeutics, Inc.’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 5:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001933414-26-000084
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Total assets | $652,862 | $661,806 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $1,116 | $2,017 |
| Accrued liabilities | 13,602 | 13,096 |
| Total current liabilities | 14,718 | 15,113 |
| Commitments and contingencies (Note 4) | ||
| Stockholders’ equity: |
Item 1. Financial Statements
FAQ
- What is Mineralys Therapeutics, Inc.'s accounts payable?
- Mineralys Therapeutics, Inc. (MLYS) reported accounts payable of $1.12M in Q1 2026.
- How has Mineralys Therapeutics, Inc.'s accounts payable changed year-over-year?
- Mineralys Therapeutics, Inc.'s accounts payable increased by 199.2% year-over-year, from $373K to $1.12M.
- What is the long-term trend for Mineralys Therapeutics, Inc.'s accounts payable?
- Over 3 years (2022 to 2025), Mineralys Therapeutics, Inc.'s accounts payable has grown at a 1.9% compound annual growth rate (CAGR), from $1.91M to $2.02M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about Mineralys Therapeutics, Inc.'s accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude